NKT Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics based on natural killer T (NKT) cells. These unique immune cells play a crucial role in human health by bridging the innate and adaptive immune systems. The company targets NKT cells to treat a range of conditions, including sickle cell disease, autoimmune and inflammatory diseases, cancer, and asthma. NKT Therapeutics' lead programs involve a set of antibodies that either inactivate or activate NKT cell functions, offering selective immune modulation. The company's business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potential future sales of their therapeutic products. NKT Therapeutics serves the healthcare market, particularly focusing on patients with chronic and severe diseases that currently have limited treatment options.

Keywords: NKT cells, biotechnology, therapeutics, cancer, autoimmune diseases, inflammatory diseases, sickle cell disease, antibodies, immune modulation, healthcare.